MEDINEX LIMITED
Incorporated in the Republic of Singapore
Registration No. 200900689W

RESPONSE TO QUERIES FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST") IN RELATION TO THE ANNOUNCEMENT MADE ON 16 SEPTEMBER 2022

The Board of Directors (the "**Board**") of Medinex Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to questions raised by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") relating to the Company's announcement dated 16 September 2022 ("**Announcement**") on the corrigendum to the announcement released on 23 January 2019 ("**Corrigendum**") and sets out its responses as follows:

Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Announcement.

Question 1 from SGX-ST:

Please disclose why the Corrigendum was only announced in September 2022 when the previous announcement was made in January 2019.

Company's response:-

The Company has recently reviewed all the previous announcements in relation to Sen Med Holdings Pte. Ltd. in light of the recent charges imposed by the Health Sciences Authority to Dr. Jitendra Kumar Sen, the director of the Company's subsidiary which was announced on 5 September 2022.

Question 2 from SGX-ST:

What was the Company's processes and procedures with regards to the preparation and review of announcements? What has changed since then?

Company's response:-

With regard to the preparation and review of announcements, the Company has always taken guidance from the SGX-ST Listing Manual Section B: Rules of Catalist ("**Catalist Rules**"). The Company prepares the relevant announcement, with the accompanying supporting documents, if any, and ensures the necessary disclosure is made as required under the Catalist Rules. Since then, the Company continues to fine-tune its internal processes even after its listing on the SGX-ST on 7 December 2018, implementing a Group-wide compliance framework and monitors its compliance with such a framework.

Question 3 from SGX-ST:

Please disclose the reviews and actions taken by the Company to prevent such omissions in future.

Company's response:-

As set out in the response to question 2 above, the Company continually fine-tunes its internal processes, monitors its Group-wide compliance framework and carries out annual internal audits to enhance the Group's internal controls and corporate governance practices. The Company will also be implementing a checklist system in relation to any corporate actions undertaken by the Company to ensure that all relevant documents are properly documented to prevent any omissions in the future. Further, the Board

has also decided that each director will be required to confirm their interests in any future acquisitions to be undertaken by the Company prior to an announcement of such nature being made.

By Order of the Board

Jessie Low Mui Choo
Executive Director and Chief Executive Officer

21 September 2022

This announcement has been prepared by the Company and reviewed by the Company's Sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.